3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Hematologic Neoplasms
4
Leukemia, Myeloid, Acute
3
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Multiple Myeloma
2
Leukemia, Myelomonocytic, Chronic
2
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Thrombocytosis
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Melanoma
1
Lymphoproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Laryngeal Neoplasms
1
Hodgkin Disease
1
Glioma
1
Interventions
fludarabine
6
Tacrolimus
6
Busulfan
6
blinatumomab
5
Rituximab
5
Cyclophosphamide
5
fludarabine phosphate
4
Peripheral Blood Stem Cell Transplantation
4
Mycophenolic Acid
4
Epoetin Alfa
4
venetoclax
3
Whole-Body Irradiation
3
Methotrexate
3
Darbepoetin alfa
3
Alemtuzumab
3
ponatinib
2
ibrutinib
2
entrectinib
2
alectinib
2
Thiotepa
2
Therapeutics
2
Patient Reported Outcome Measures
2
Mesna
2
Melphalan
2
Everolimus
2
Early Intervention, Educational
2
Bone Marrow Transplantation
2
Antilymphocyte Serum
2
vandetanib
1
trametinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoproliferative Disorders
×
cobimetinib
×
Other hematologic neoplasm
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled